전체메뉴

Journal of Pharmacopuncture

Article Search

JoP

Best Practice

Compliance of Journal of Pharmacopuncture to the Principles of transparency and best practice in scholarly publishing
(joint statement by COPE, DOAJ, WAME, and OASPA;- http://doaj.org/bestpractice)

Enacted March 19, 2020

  • 1. Website:
    • i. The URL address of official journal web site: https://www.journal-jop.org
      ii. ‘Aims & Scope’ statement:

      Aims
      The Journal of Pharmacopuncture is an international, peer-reviewed open-access journal published in English by the Korean Pharmacopuncture Institute (KPI). The journal has provided high-quality papers quarterly since it was launched in 1997. Its ISSN was changed in September 2010
      from 1226-4849 to 2093-6966 when its title was changed from Daehanyakchimhakhweiji to the Journal of Pharmacopuncture. The journal aims to publish evidence-based, scientific research papers in the multidisciplinary field of traditional and modern medicine through a strict review process by a panel of experts. As an international journal, the Journal of Pharmacopuncture also aims to present major advances and new developments contributing to the advancement of complementary and alternative medicine, with a special focus on pharmacology, acupuncture and a combination of pharmacology and acupuncture. The journal is dedicated to disseminating current data and ideas and fostering debate on issues related to complementary and alternative medicine and to providing better information to both the general public and experts. In addition, the journal requires high standards of research ethics to maintain the integrity of science. The official title of the journal is 'Journal of Pharmacopuncture', and the abbreviated title is 'J. Pharmacopunct.' For submission, see the details at http://www.journal-jop.org

      Scope
      The Journal of Pharmacopuncture covers a wide range of basic and clinical science research relevant to all aspects of the biotechnology of integrated approaches using both pharmacology and acupuncture therapeutics, including research involving pharmacology, acupuncture studies and pharmacopuncture studies. The subjects are mainly divided into three categories: pharmacology (applied phytomedicine, plant sciences, pharmacology, toxicology, medicinal plants, traditional medicines, herbal medicine, Sasang constitutional medicine, herbal formulae, foods, agricultural technologies, naturopathy, etc.), acupuncture (acupressure, electroacupuncture, laser acupuncture, moxibustion, cupping, etc.), and pharmacopuncture (aqua-acupuncture, meridian pharmacopuncture, eight-principles pharmacopuncture, animal-based pharmacopuncture, mountain ginseng pharmacopuncture, bee venom therapy, needle embedding therapy, implant therapy, etc.). Other categories include chuna treatment, veterinary acupuncture and related animal studies, alternative medicines for treating cancer and cancer-related symptoms, etc. Broader topical coverage on the effects of acupuncture, the medical plants used in traditional and alternative medicine, pharmacological action and other related modalities, such as anthroposophy, homeopathy, ayurveda, bioelectromagnetic therapy, chiropractic, neural therapy and meditation, can be considered to be within the journal's scope if based on acupoints and meridians.
      iii. Readership: JoP is primarily for medical researchers and clinicians of acupuncture, traditional medicine, integrative medicine, complementary and alternative medicine, and other personnel who work in the field of medicine. Its readership can be expanded to other positions related to subjects described in aims and scope.
      iv. Authorship criteria: The authorship should be given according to 1) making substantial contribution to the conception and design of the study, or acquisition, interpretation and analysis of data; 2) drafting the article or revising it critically for the important intellectual content; and 3) final approval of the version to be published. When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
      v. Duplicate submission and redundant publication: Submitted manuscripts must not have been previously published or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. Submitted manuscripts are screened for possible plagiarism or duplicate publication by Similarity Check upon arrival. If plagiarism or duplicate publication is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutions will be informed. There will also be penalties for the authors. A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, figures, and tables.
      vi. pISSN: 2093-6966 eISSN: 2234-6856
  • 2. Name of journal
    • The official title of the journal is 'Journal of Pharmacopuncture', and the abbreviated title is 'J. Pharmacopunct.'
  • 3. Peer review process
    • We adopt the double-blind peer review.

      Reviewers are assigned to a submitted paper for peer review.

      Anything indicating identification of authors is removed from the papers assigned for review. The invited reviewers should give a review of the assigned paper within 15 days after agreeing to do review.

      Reviewers classify the paper as accepted in present form, minor revision (accepted after modest revisions), major revision (reconsidered for acceptance after major changes), and rejected at this stage.

      When the paper is evaluated as minor revision (accepted after modest revisions), the reviewers should specify where should be made corrections. Revised papers are put under a second review by the reviewers or the Editorial Board members to determine whether they are acceptable in revised form.

      When a paper is evaluated as major revision (reconsidered for acceptance after major change), the reviewers should specify where should be made corrections. Revised papers are put under a second review by the reviewers or the Editorial Board members to determine whether they are acceptable in revised form.

      When the paper is rejected at this stage, the reviewers should cite specific reasons as to how the decision was reached.

      Review results will be sent to the authors once the required reviews are completed.

      Reviewers should post review results on the website of the Journal of Pharmacopuncture. Emails from reviewers and authors are considered as digital signatures.
  • 4. Ownership and management
  • 5. Governing body
    • The governing body is the journal’s editorial board.
  • 6. Editorial team and contact information
    • i. Editorial team is available from the Editorial Board page at the front part of the journal.
      ii. Contact information
      Seokhyun Kang
      JoP Editorial office
      4F AKOM Building, 91, Heojun-ro, Gangseo-gu, Seoul 07525, Korea, Tel: +82-2-2658-9051, Fax: +82-2-2658-9136, E-mail: kpi-jpharmaco@naver.com
  • 7. Copyright and licensing
    • i. Copyright policy: Published manuscripts become the permanent property of the Korean Pharmacopuncture Institute and may not be published elsewhere in any form without written permission.

      ii. Licensing information: JOP Journals are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge & be non-commercial, they don't have to license their derivative works on the same terms.

      Published Open Access articles are distributed under this Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC). Articles can be read and shared for noncommercial purposes under the following conditions:

      BY: Attribution must be given to the original source (Attribution) NC: Works may not be used for commercial purposes (Noncommercial) JOP Journals use the CC BY-NC to protect the author's work from misuse. For more information about creative commons licences, please see: https://creativecommons.org
  • 8. Author fees
    • Neither page charge, article processing charge (also known as a publication fee) for accepted articles nor submission fee will be applied. It is the platinum open access journal.
  • 9. Process for the identification of and dealing with allegations of research misconduct
    • When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.
  • 10. Publication ethics
    • i. Journal policies on authorship and contributorship: It is described at the Instructions to authors.
      ii. How the journal will handle complaints and appeals: The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals
      • Who complains or makes an appeal?: Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter to the editor. For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
      • Who is responsible to resolve and handle complaints and appeals?: The Editor, Editorial Board, or Editorial Office is responsible for them.
      • What may be the consequence of remedy?: It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee on Publication Ethics (COPE).
      iii. Journal policies on conflicts of interest / competing interests: It is described at the Instructions to authors.
      iv. Journal policies on data sharing and reproducibility; Open data policy: For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository after acceptance of the manuscript. Therefore, the submission of the raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data or waiver of data sharing, the authors should contact the editorial office. Clinical data sharing policy: This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://synapse.koreamed.org/Synapse/Data/PDFData/0063JKMS/jkms-32-1051.pdf). The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.
      If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
      v. Journal's policy on ethical oversight: When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, and ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). All studies involving human subjects or human data must be reviewed and approved by a responsible Institutional Review Board (IRB). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
      vi. Journal's policy on intellectual property: All published papers become the permanent property of the Korean Pharmacopuncture Institute. Copyrights of all published materials are owned by the Korean Pharmacopuncture Institute.
      vii. Journal's options for post-publication discussions and corrections: The post-publication discussion is available through letter to editor. If any readers have a concern on any articles published, they can submit letter to editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through erratum, corrigenda, or retraction.
  • 11. Publishing schedule
    • It is to be published quarterly. Supplement issues may be published.
  • 12. Access
    • This is an open-access journal distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative (CC BY-NC) license, which is for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s).
  • 13. Archiving
  • 14. Revenue sources
    • Revenue sources of journal are from the support of publisher (Korean Pharmacopuncture Institute), Korea Government’s support, and advertising rates.
  • 15. Advertising
    • Journal of Pharmacopuncture accepts any advertisements on the following basis:

      Eligibility of the advertised products or services
      All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.
      - Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.
      - We reserve the right to decline or cancel any advertisement at any time.
      - Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea in every respect.

      Orders
      Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisements will be discussed by the editorial board and will be ultimately approved by the publisher.

      Advertisement fee
      For one print copy issue, the advertisement price for one whole page is USD 1,000 (or KRW 1,000,000). If the advertisement is half a page, the price is reduced by half. For a quarter of the page, this price is reduced by one quarter.

      Disclaimer Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the journal. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
      Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
      Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.
  • 16. Direct marketing
    • Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.

Journal Info

JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
March, 2021
Vol.24 No.1

pISSN 2093-6966
eISSN 2234-6856
Quarterly

Archives >

Editorial Office

Fax
Fax +82-2-2658-9136

Most Read / Downloaded

  • Review Article2020-06-30

    Abstract : Coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). Currently, the management of patients with COVID-19 depends mainly on repurposed drugs which include chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, remdesivir, favipiravir, umifenovir, interferon-α, interferon-β and others. In this review, the potential of Nigella sativa (black cumin seeds) to treat the patients with COVID-19 analyzed, as it has shown to possess antiviral, antioxidant, anti-inflammatory, anticoagulant, immunomodulatory, bronchodilatory, antihistaminic, antitussive, antipyretic and analgesic activities. PubMed, Google Scholar, Science Direct, Directory of open access journals (DOAJ) and reference lists were searched to identify articles associated with antiviral and other properties of N.sativa related to the signs and symptoms of COVID-19. Various randomized controlled trials, pilot studies, case reports and in vitro and in vivo studies confirmed that N.sativa has antiviral, antioxidant, anti-inflammatory, immunomodulatory, bronchodilatory, antihistaminic, antitussive activities related to causative oraganism and signs and symptoms of COVID-19. N. sativa could be used as an adjuvant therapy along with repurposed conventional drugs to manage the patients with COVID-19.

    Abstract
  • Systematic Review2020-06-30

    Bee Venom Acupuncture for Shoulder Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    Lei Shen1,†, Jong Ha Lee2,†, Jong Cheon Joo1, Soo Jung Park3,*, and Yung Sun Song4,*
    J Pharmacopuncture 2020; 23(2): 44-53 https://doi.org/10.3831/KPI.2020.23.008

    Abstract : ObjectivesOur review aimed to summarize and evaluate evidence on the effectiveness of bee venom acupuncture (BVA) in the treatment of shoulder pain.MethodsRandomized controlled trials (RCTs) evaluating the effectiveness of BVA on shoulder pain were searched up to October 2019 in 11 electronic databases (Medline, Embase, CENTRAL, CiNii, CNKI, VIP, Wanfang, Kmbase, NDSL, RISS, OASIS). The methodological quality of the included RCTs were evaluated using Cochrane Risk of Bias tool and a meta-analysis was performed.ResultsSeven studies were included in the review, and four studies were included in the meta-analysis. Comparing BVA plus conventional therapy (CT) with saline injection plus CT, it showed an effect in favor of BVA plus CT in visual analog scale (VAS) and pain rating scale (PRS) (p = 0.02, p = 0.009, respectively). Comparing BVA plus physiotherapy (PT) with saline injection plus PT, it showed that there was no significant difference in VAS and verbal rating scale (VRS) between the two groups.ConclusionThis systematic review and meta-analysis suggest that BVA could be beneficial as an adjuvant treatment for shoulder pain.

    Abstract
  • Review Article2020-09-30
    JoP

    Ethnomedicinal Uses, Phytochemistry and Pharmacology of Dorema Species (Apiaceae): A Review

    Elaheh Zibaee1, Mohammad Sadegh Amiri2, Zahra Boghrati1, Faeghe Farhadi3, Mahin Ramezani4,5, Seyed Ahmad Emami1*, Amirhossein Sahebkar6,7,8,9
    J Pharmacopuncture 2020; 23(3): 91-123 https://doi.org/10.3831/KPI.2020.23.3.91

    Abstract : The application of antique medical instructions, practices, skills and knowledge has been considered as the most affordable treatment in many developing countries. The use of these preparations and prescriptions over generations has made a useful and valuable guide for drug discovery in modern medicine. Medical herbs have been of a high importance for this purpose. The genus Dorema, of Apiaceae family (Umbelliferae) has a wide use in ethnobotany and traditional medicine around the world. It has been used as a treatment for CNS disease, convulsion, upper respiratory tract problems, gastrointestinal disorder and high blood sugar. Furthermore, phytochemical investigations have reported Dorema species to contain a wide range of constituents including terpenes, coumarins and phenolic compounds. The current review summarizes comprehensive information regarding botany, phytochemistry andpharmacological aspects of Dorema spp.

    Abstract
All Newest Articles
  • Review Article2020-06-30

    Abstract : Coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). Currently, the management of patients with COVID-19 depends mainly on repurposed drugs which include chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, remdesivir, favipiravir, umifenovir, interferon-α, interferon-β and others. In this review, the potential of Nigella sativa (black cumin seeds) to treat the patients with COVID-19 analyzed, as it has shown to possess antiviral, antioxidant, anti-inflammatory, anticoagulant, immunomodulatory, bronchodilatory, antihistaminic, antitussive, antipyretic and analgesic activities. PubMed, Google Scholar, Science Direct, Directory of open access journals (DOAJ) and reference lists were searched to identify articles associated with antiviral and other properties of N.sativa related to the signs and symptoms of COVID-19. Various randomized controlled trials, pilot studies, case reports and in vitro and in vivo studies confirmed that N.sativa has antiviral, antioxidant, anti-inflammatory, immunomodulatory, bronchodilatory, antihistaminic, antitussive activities related to causative oraganism and signs and symptoms of COVID-19. N. sativa could be used as an adjuvant therapy along with repurposed conventional drugs to manage the patients with COVID-19.

    Abstract
  • Review Article2020-09-30

    A Literature Analysis on Medicinal Use and Research of Cannabis in the Meiji Era of Japan

    Byung-Soo Ahn1,4, Seokhyun Kang2, Kyung Hoon Lee3, Seoyoon Kim1, Jin Sung Park1, Hyung-Sik Seo5*
    J Pharmacopuncture 2020; 23(3): 142-157 https://doi.org/10.3831/KPI.2020.23.3.142

    Abstract : Cannabis is a historical plant which has been used as a medicine in East Asia. These days, there are active debates about using cannabis in clinical field. Collecting and comparing cannabis research articles which had been published in the Opening of Japan to spot the interactions between the traditional medicine of Japan, Rangaku which was established in Edo Period and the European medicine which is transferred after Perry Expedition is academically meaningful. This study searched publications, which were listed on Open-Access databases by Dec. 11th, 2019. We collected research articles which had been published from January 3rd, 1867 to July 30th, 1912 also known as Meiji era and uploaded on Open-Access databases. Our searching databases were J-stage, CiNii (Scholarly and Academic Information Navigator), Tokyo Metropolitan Library, The National Diet Library, IRDB (Institutional Repositories DataBase) and KAKEN (Grant-in-Aid for Scientific Research Database). Searching keywords were cannabis, hemp and all their Japanese synonyms and available combinations. We selected final 15 studies which met every selection criteria in the 346,393 collected studies. Cannabis was prescribed in Meiji era of Japan to alleviate pain and cure the digestive, respiratory, urinary, and nervous system diseases such as indigestion, asthma, tuberculosis, gonorrhea and its complications, insomnia, and nervous prostration. Cannabis was medically used in Meiji era of Japan and the reporting and sharing of its clinical effect was published on the medical journals like present days. There were already Cannabis regulations in that era, but its medicinal use was more liberated than nowadays. It may be a chance to reconsider the current legal system, which strictly controls the use of Cannabis.

    Abstract
  • Original Article2020-09-30

    Abstract : Objectives: Atopic dermatitis (AD) is a prevalent and chronic, pruritic inflammatory skin condition that can influence all age groups. AD is associated with a poor health-related quality of life. This randomized clinical trial was performed to compare the effectiveness of Olivederma (combination of aloe vera and virgin olive oil) or betamethasone regarding disease severity, quality of life, serum IgE and eosinophil count. Methods: Thirty-six AD patients were randomly allocated to topical Olivederma or betamethasone, and were followed for 6 weeks. Results: Total SCORAD severity scores showed significant decrease in both groups, while it was more prominent in Olivederma group (64.5% improvement in Olivederma vs. 13.5% improvement in Betamethasone, p-value < 0.001). Quality of life (DLQI questionnaire) of AD patients was significantly improved after 6 weeks treatment with Betamethasone (22.3%, p < 0.001) and Olivederma (60.7%, p-value < 0.001). Olivederma group showed a significantly lower DLQI score in comparison with Betamethasone treated patients after 6 weeks of therapy (p < 0.001). Improvements in eosinophil count and serum IgE was observed. Conclusion: In summary, this study shows that Olivederma is superior to topical Betamethasone after 6 weeks of therapy with regard to disease severity, quality of life and eosinophil count.

    Abstract
All Newest Articles

Scimago Journal & Country Rank

SCImago Journal & Country Rank